Fibrodysplasia ossificans progressiva-When bone suddenly forms within muscle

被引:0
|
作者
Grossmann, Nadine Z. [1 ,2 ]
Hildebrandt, Susanne [1 ,2 ]
Morhart, Rolf [3 ]
Kallinich, Tilmann [4 ]
Semler, Oliver [5 ,6 ]
Knaus, Petra [1 ,2 ,7 ]
机构
[1] Free Univ Berlin, Inst Chem Biochem, Berlin, Germany
[2] Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Charite, Berlin, Germany
[3] Klinikum Garm Partenkirchen, Kinder & Jugendmedizin, Garmisch Partenkirchen, Germany
[4] Univ Med Berlin, Padiatr Rheumatol, Charite, Berlin, Germany
[5] Univ Cologne, Med Fak, Cologne, Germany
[6] Uniklin Koln, Klinik Poliklin Kinder & Jugendmed, Cologne, Germany
[7] Free Univ Berlin, Inst Chem & Biochem, Thielallee 63, D-14195 Berlin, Germany
关键词
Fibrodysplasia ossificans progressiva; Heterotopic ossification; Myositis ossificans; Soft tissue swelling; Congenital hallux valgus; FOP;
D O I
10.1007/s00112-023-01816-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic condition caused by a point mutation in the ACVR1 gene. There are two clinical features indicative of FOP: 1) a congenital malformation of the great toe(s), similar to a hallux valgus and 2) unexplained soft tissue swelling usually resulting in heterotopic ossifications (HO). Early recognition of these two features is very important to avoid misdiagnosis and incorrect treatment and to ensure the correct diagnosis as early as possible by genetic testing of the ACVR1 gene. As soon as this diagnosis is available it is advisable for the affected person to see a FOP specialist and to establish contact with the German patient organization "FOP e. V.".All invasive interventions should be strictly avoided, as they can trigger irreversible HO. The complexity and systemic course of FOP requires the establishment and collaboration of an interdisciplinary team for optimal care of affected individuals. Treatment of FOP flare-ups and subsequent ossification is currently symptomatic according to the international guidelines of the ICC on FOP (www.iccfop.org). Targeted treatment approaches in current clinical trials aim to influence the bone morphogenetic protein (BMP) signalling pathway at multiple levels to halt or slow disease progression.While more than 95% of all affected individuals have the classical point mutation, a small number of affected individuals have variant mutations. Each of these mutations leads to hypersensitivity and overactivation of the ACVR1 receptor and results in an increased BMP signalling response.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Mutational screening of the bone morphogenetic protein 4 gene in a family with fibrodysplasia Ossificans Progressiva.
    Shore, E
    Xu, MQ
    Kaplan, F
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : S642 - S642
  • [42] The HLA-B27 antigen is not correlated with the heterotopic bone in fibrodysplasia Ossificans Progressiva.
    Calvert, G
    Kalan, F
    Shore, E
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : S641 - S641
  • [43] Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography
    Farid, Alexander
    Golden, Emma
    Robicheau, Sara
    Hu, Alice
    Cheung, Kin
    Yu, Paul B.
    Rutkove, Seward B.
    Upadhyay, Jaymin
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [44] The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva
    Zhengqin Ye
    Siyi Wang
    Chang Shan
    Qi Zhu
    Ying Xue
    Keqin Zhang
    Orphanet Journal of Rare Diseases, 18
  • [46] Characterization of mechanisms controlling bone morphogenetic protein 4 message expression in fibrodysplasia ossificans progressiva.
    Olmsted, EA
    Liu, C
    Haddad, JG
    Shore, EM
    Kaplan, FS
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : P294 - P294
  • [47] Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography
    Alexander Farid
    Emma Golden
    Sara Robicheau
    Alice Hu
    Kin Cheung
    Paul B. Yu
    Seward B. Rutkove
    Jaymin Upadhyay
    Scientific Reports, 12 (1)
  • [48] FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - BIOCHEMICAL CHANGES IN BLOOD-SERUM, URINE, SKIN, BONE, AND ECTOPIC OSSIFICATION
    BLUMENKRANTZ, N
    ASBOEHANSEN, G
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1978, 7 (02) : 85 - 89
  • [49] Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [18F]NaF PET/CT study
    Botman, Esmee
    Raijmakers, Pieter G. H. M.
    Yaqub, Maqsood
    Teunissen, Bernd
    Netelenbos, Coen
    Lubbers, Wouter
    Schwarte, Lothar A.
    Micha, Dimitra
    Bravenboer, Nathalie
    Schoenmaker, Ton
    de Vries, Teun J.
    Pals, Gerard
    Smit, Jan Maerten
    Koolwijk, Pieter
    Trotter, Dinko Gonzalez
    Lammertsma, Adriaan A.
    Eekhoff, E. Marelise W.
    BONE, 2019, 124 : 1 - 6
  • [50] TRAUMATIC FRACTURES OF HETEROTOPIC BONE IN PATIENTS WHO HAVE FIBRODYSPLASIA-OSSIFICANS-PROGRESSIVA - A REPORT OF 2 CASES
    EINHORN, TA
    KAPLAN, FS
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1994, (308) : 173 - 177